Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Money in biomedicine: The senator's sleuth

Paul Thacker, a reporter-turned-Congressional-investigator, has disrupted the careers of several top researchers with lucrative industry ties. Meredith Wadman tracks his effect on US science.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Authors

Additional information

See Editorial, page 315 .

Related links

Related links

Related external links

Senate Finance Committee compendium of hyperlinks to Nemeroff-related documents

Senate Finance Committee archive of news stories by targeted investigator

Emory University index of hyperlinks on conflict and Nemeroff-related announcements

National Institutes of Health proposed rules changes on conflict disclosure for extramural investigators

SE Journal, summer 2007: Thacker's account of his ouster from Environmental Science and Technology, and Rudy Baum's written response

Association of Clinical Researchers and Educators

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wadman, M. Money in biomedicine: The senator's sleuth. Nature 461, 330–334 (2009). https://doi.org/10.1038/461330a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/461330a

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing